Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Department of Health and Human Services
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant
Funding
Award size
$100K – $1M
Award ceiling
150000
Type
Grant
Dates
Deadline
Later
Posted
06/03/2026
Closes
2026-11-10
Eligibility
Eligibility
Special district governmentsFor profit organizations other than small businessesPrivate institutions of higher educationCounty governmentsSmall businessesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationState governmentsPublic housing authorities/Indian housing authoritiesCity or township governmentsIndependent school districtsPublic and State controlled institutions of higher educationNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNative American tribal governments (Federally recognized)Others (see text field entitled "Additional Information on Eligibility" for clarification)
Program
Funding area
Health - HL
Opportunity #
RFA-CA-27-001
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov